Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-06-15
Target enrollment:
Participant gender:
Summary
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an
anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. This is a dose escalation study to
identify the maximum toxicity dose (MTD) or the recommended phase 2 dose (RP2D).